June 21, 2018

Chasing the Next Biotech Unicorn

How private equity sets to thrive in the biotech boom in Hong Kong

New listing rules in Hong Kong for biotech and the healthcare reform in China are propelling capital raising activities in the region. Rocketed valuation in the biotech sector drives interest from private equity investments, who demand swift investment cycle with a clear profit-making path for going public. The importance of rigorous and timely pre-investment screening and due diligence process is at an all-time high.

Download this whitepaper to examine the potential opportunities and headwinds in the biotech state-of-play, as well as factors that would drive deal success.

Fill out the form to download this whitepaper.

© 2021 Datasite All rights reserved

Datasite provides secure software solutions for managing the full spectrum of financial transactions — including M&A, restructuring & administration, and capital raising. Our intuitive platform offers ironclad security enabling file sharing and collaboration within and across organizations. More than a virtual data room (VDR), Datasite supports advisors and their clients across the entire deal lifecycle with secure collaborative software that shortens timelines for buy-side and sell-side teams from deal sourcing and deal preparation to post-merger integration (PMI) while meeting regulatory compliance — including GDPR and CCPA requirements. As the premiere virtual data room for M&A due diligence globally, Datasite is consistently recognized for breakthrough technologies like our AI/ML-enabled capabilities and automated redaction tools. Beyond due diligence, Datasite provides transaction and document management solutions for investment banks, corporate development, private equity, and law firms across industries.